Study to Evaluate the Efficacy and Safety of SLV306 in Subjects With Hypertension
A Randomized, Placebo-Controlled, Double-Blind, Six-Arm, Dose Escalation, Multi-Center Study to Evaluate the Efficacy and Safety of SLV306: 150, 300, 600 mg Once Daily, 150-300 mg Twice Daily and Amlodipine 5-10 mg Once Daily in Subjects With Hypertension
2 other identifiers
interventional
N/A
11 countries
130
Brief Summary
This study is to compare the efficacy and safety of increasing doses of SLV306 with amlodipine.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
130 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2004
CompletedFirst Submitted
Initial submission to the registry
September 9, 2005
CompletedFirst Posted
Study publicly available on registry
September 12, 2005
CompletedJanuary 30, 2009
January 1, 2009
September 9, 2005
January 29, 2009
Conditions
Keywords
Interventions
Eligibility Criteria
You may qualify if:
- sitting office diastolic blood pressure between 90 and 109 mmHg
- office systolic blood pressure between 140 and 179 mmHg
- mean day-time diastolic 24-h ABPM blood pressure \>= 85 mmHg inclusive at baseline
You may not qualify if:
- known secondary hypertension
- decompensated congestive heart failure
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (130)
Site 705
Bracken Ridge, Australia
Site 706
Caboolture, Australia
Site 700
Inala, Australia
Site 701
Kippa-Ring, Australia
Site 702
Melbourne, Australia
Site 703
Nedlands, Australia
Site 952
Haskovo, Bulgaria
Site 955
Pleven, Bulgaria
Site 951
Plovdiv, Bulgaria
Site 956
Plovdiv, Bulgaria
Site 950
Sofia, Bulgaria
Site 953
Sofia, Bulgaria
Site 954
Sofia, Bulgaria
Site 957
Sofia, Bulgaria
Site 402
Aalborg, Denmark
Site 401
Ballerup Municipality, Denmark
Site 403
Vejle, Denmark
Site 850
Tallinn, Estonia
Site 119
Aschaffenburg, Germany
Site 101
Bad Nauheim, Germany
Site 104
Bad Wörishofen, Germany
Site 106
Beckum, Germany
Site 110
Deidesheim, Germany
Site 107
Karlsruhe, Germany
Site 118
Kassel, Germany
Site 109
Krombach, Germany
Site 113
Ladenburg, Germany
Site 102
Leipzig, Germany
Site 112
Lollar, Germany
Site 114
Magdeburg, Germany
Site 111
Marburg, Germany
Site 105
Münster, Germany
Site 115
Niederstetten, Germany
Site 120
Rodgau Dudenhofen, Germany
Site 116
Vellmar, Germany
Site 103
Wiesbaden, Germany
Site 117
Wolmirstedt, Germany
Site 800
Budapest, Hungary
Site 805
Budapest, Hungary
Site 803
Gyöngyös, Hungary
Site 801
Kecskemét, Hungary
Site 804
Pécs, Hungary
Site 802
Székesfehérvár, Hungary
Site 300
Ashkelon, Israel
Site 306
Ashkelon, Israel
Site 304
Beersheba, Israel
Site 311
Haifa, Israel
Site 305
Jerusalem, Israel
Site 310
Kfar Saba, Israel
Site 303
Kiryat Ata, Israel
Site 308
Petah Tikva, Israel
Site 302
Tel Aviv, Israel
Site 301
Tel Litwinsky, Israel
Site 309
Tiberias, Israel
Site 932
Daugavpils, Latvia
Site 930
Kuldīga, Latvia
Site 931
Riga, Latvia
Site 933
Riga, Latvia
Site 934
Riga, Latvia
Site 935
Riga, Latvia
Site 920
Kaunas, Lithuania
Site 923
Klaipėda, Lithuania
Site 921
Vilnius, Lithuania
Site 600
Bratislava, Slovakia
Site 601
Bratislava, Slovakia
Site 607
Košice, Slovakia
Site 608
Košice, Slovakia
Site 602
Levice, Slovakia
Site 605
Lučenec, Slovakia
Site 603
Nové Zámky, Slovakia
Site 606
Vráble, Slovakia
Site 262
Addlestone, United Kingdom
Site 229
Airdrie, United Kingdom
Site 234
Alexandria, United Kingdom
Site 245
Bangor, United Kingdom
Site 241
Barrhead, United Kingdom
Site 224
Bath, United Kingdom
Site 240
Bath, United Kingdom
Site 230
Bellshill, United Kingdom
Site 243
Bexhill-on-Sea, United Kingdom
Site 261
Bexhill-on-Sea, United Kingdom
Site 255
Blackpool, United Kingdom
Site 222
Blantyre, United Kingdom
Site 232
Calderbank, United Kingdom
Site 236
Chesterfield, United Kingdom
Site 219
Chippenham, United Kingdom
Site 256
Chippenham, United Kingdom
Site 237
Co Tyrone, United Kingdom
Site 216
Coatbridge, United Kingdom
Site 238
Cornwall, United Kingdom
Site 207
Coventry, United Kingdom
Site 247
Cumbernauld, United Kingdom
Site 208
Dumbarton, United Kingdom
Site 235
East Horsley, United Kingdom
Site 220
Ely, United Kingdom
Site 257
Frome, United Kingdom
Site 210
Glasgow, United Kingdom
Site 221
Glasgow, United Kingdom
Site 227
Glasgow, United Kingdom
Site 233
Glasgow, United Kingdom
Site 251
Glasgow, United Kingdom
Site 201
Greenisland, United Kingdom
Site 252
Helensburgh, United Kingdom
Site 249
Hook, United Kingdom
Site 226
Maidenhead, United Kingdom
Site 246
Maidenhead, United Kingdom
Site 213
Manchester, United Kingdom
Site 244
Melksham, United Kingdom
Site 259
Middlesex, United Kingdom
Site 202
Motherwell, United Kingdom
Site 206
Motherwell, United Kingdom
Site 217
Motherwell, United Kingdom
Site 239
Motherwell, United Kingdom
Site 231
Paisley, United Kingdom
Site 250
Paisley, United Kingdom
Site 242
Penzance, United Kingdom
Site 218
Plymouth, United Kingdom
Site 223
Plymouth, United Kingdom
Site 254
Reading, United Kingdom
Site 212
Riddrie, United Kingdom
Site 200
Royal Leamington Spa, United Kingdom
Site 253
Sandy, United Kingdom
Site 258
Sheffield, United Kingdom
Site 205
Slough, United Kingdom
Site 215
St Just, United Kingdom
Site 211
Strathaven, United Kingdom
Site 225
Swansea, United Kingdom
Site 209
Thornhill, United Kingdom
Site 248
Woking, United Kingdom
Site 228
Wokingham, United Kingdom
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Global Clinical Director Solvay
Solvay Pharmaceuticals
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
September 9, 2005
First Posted
September 12, 2005
Study Start
December 1, 2004
Last Updated
January 30, 2009
Record last verified: 2009-01